Agendia
Becton Dickinson, DiaSorin, Roche Obtain FDA 510(k) Clearances in September
The clearances from the US Food and Drug Administration include a prognostic assay for breast cancer metastasis, a G6PD deficiency test, and a COVID-19 detection kit.
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market
Premium
The firm is offering access in Brazil to a digital assay that provides genomic insights using technology developed in a collaboration with computational pathology firm Paige.
Agendia to Distribute Inivata Liquid Biopsy Breast Cancer Test in North America, Europe
Agendia will receive co-exclusive rights to distribute Inivata's RaDaR assay for minimal residual disease and relapse detection in Europe and North America.
Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.